Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Hold” at Stifel Nicolaus

Stifel Nicolaus downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report released on Thursday morning, The Fly reports. Stifel Nicolaus currently has $23.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $55.00.

A number of other research analysts have also issued reports on SUPN. Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 7th. Mizuho reiterated a buy rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, August 7th. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday. TheStreet lowered shares of Supernus Pharmaceuticals from a b- rating to a c+ rating in a research note on Thursday, August 29th. Finally, BidaskClub upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company’s stock. Supernus Pharmaceuticals has an average rating of Hold and an average target price of $46.50.

SUPN stock traded up $0.57 on Thursday, hitting $21.72. 1,010,300 shares of the company’s stock traded hands, compared to its average volume of 579,923. The stock has a fifty day moving average of $26.80 and a 200-day moving average of $30.29. Supernus Pharmaceuticals has a 1-year low of $19.35 and a 1-year high of $49.25. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of 10.60, a P/E/G ratio of 1.02 and a beta of 1.63. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.05). Supernus Pharmaceuticals had a net margin of 25.92% and a return on equity of 21.80%. The firm had revenue of $102.14 million during the quarter, compared to analyst estimates of $108.70 million. During the same quarter in the previous year, the business posted $0.52 earnings per share. The business’s quarterly revenue was down .8% compared to the same quarter last year. On average, equities research analysts anticipate that Supernus Pharmaceuticals will post 2.14 earnings per share for the current fiscal year.

In related news, CEO Jack A. Khattar purchased 7,200 shares of Supernus Pharmaceuticals stock in a transaction on Friday, August 23rd. The stock was purchased at an average cost of $26.39 per share, with a total value of $190,008.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 6.57% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Supernus Pharmaceuticals by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock valued at $176,873,000 after purchasing an additional 49,676 shares during the period. Rice Hall James & Associates LLC boosted its holdings in Supernus Pharmaceuticals by 35.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock valued at $44,714,000 after purchasing an additional 350,905 shares during the period. Macquarie Group Ltd. boosted its holdings in Supernus Pharmaceuticals by 8.5% in the 2nd quarter. Macquarie Group Ltd. now owns 1,079,001 shares of the specialty pharmaceutical company’s stock valued at $35,705,000 after purchasing an additional 84,846 shares during the period. Neumeier Poma Investment Counsel LLC boosted its holdings in Supernus Pharmaceuticals by 1.1% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock valued at $31,680,000 after purchasing an additional 10,170 shares during the period. Finally, Provident Investment Management Inc. boosted its holdings in Supernus Pharmaceuticals by 13.8% in the 2nd quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock valued at $24,034,000 after purchasing an additional 88,099 shares during the period. 99.14% of the stock is owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: How to calculate the annual rate of depreciation

The Fly

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.